Autifony Therapeutics Ltd., of Stevenage, U.K., said it achieved the first milestone under its option agreement with Ingelheim, Germany-based Boehringer Ingelheim GmbH that has an exclusive option to purchase Autifony's Kv3.1/3.2 positive modulator platform. The lead molecule, AUT-00206, is covered in the agreement, which is in a phase Ib trial in patients with schizophrenia.